Publication:
Severe T2-high asthma in the biologics era: European experts' opinion

Simple item page
dc.contributor.authorPavord, Ian
dc.contributor.authorBahmer, Thomas
dc.contributor.authorBraido, Fulvio
dc.contributor.authorGarcía-Cosío, Borja
dc.contributor.authorHumbert, Marc
dc.contributor.authorIdzko, Marco
dc.contributor.authorAdamek, Lukasz
dc.date.accessioned2024-09-10T13:08:54Z
dc.date.available2024-09-10T13:08:54Z
dc.date.issued2019-06-30
dc.description.abstractThe European Respiratory Biologics Forum gathered participants from 21 countries in Madrid, Spain, to discuss the management and treatment of severe asthma in the era of biologics. The current insights on the pathophysiology of severe asthma were discussed, as well as the role of respiratory biologics in clinical practice and strategies for eliminating chronic use of oral corticosteroids. The participants also highlighted the key challenges in identifying patients with severe asthma based on phenotypes, biomarkers and treatable traits, and the existing problems in patient referral to specialist care. The monitoring of treatment was debated and the need for a change towards precision medicine and personalised care was emphasised throughout the meeting. This review provides a summary of the discussions and highlights important concerns identified by the participants regarding the current management of severe asthma.en
dc.description.sponsorshipThe study was funded and supported by AstraZeneca. Funding information for this article has been deposited with the Crossref Funder Registry.es_ES
dc.format.number152es_ES
dc.format.page190054es_ES
dc.format.volume28es_ES
dc.identifier.citationPavord I, Bahmer T, Braido F, Cosio BG, Humbert M, Idzko M, et al. Severe T2-high asthma in the biologics era: European experts' opinion. Eur Respir Rev. 2019 Jun 30;28(152):190054.en
dc.identifier.doi10.1183/16000617.0054-2019
dc.identifier.e-issn1600-0617es_ES
dc.identifier.issn0905-9180
dc.identifier.journalEuropean Respiratory Reviewes_ES
dc.identifier.otherhttp://hdl.handle.net/20.500.13003/17440
dc.identifier.pubmedID31285291es_ES
dc.identifier.puiL2002404964
dc.identifier.scopus2-s2.0-85069307012
dc.identifier.urihttps://hdl.handle.net/20.500.12105/22703
dc.identifier.wos477993000004
dc.language.isoengen
dc.publisherEuropean Respiratory Society (ERS)
dc.relation.publisherversionhttps://dx.doi.org/10.1183/16000617.0054-2019en
dc.rights.accessRightsopen accessen
dc.rights.licenseAttribution-NonCommercial 4.0 International*
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/*
dc.subject.decsConsenso*
dc.subject.decsResultado del Tratamiento*
dc.subject.decsHumanos*
dc.subject.decsAntiasmáticos*
dc.subject.decsAsma*
dc.subject.decsFenotipo*
dc.subject.decsÍndice de Severidad de la Enfermedad*
dc.subject.decsProductos Biológicos*
dc.subject.decsPulmón*
dc.subject.meshAsthma*
dc.subject.meshLung*
dc.subject.meshPhenotype*
dc.subject.meshBiological Products*
dc.subject.meshSeverity of Illness Index*
dc.subject.meshAnti-Asthmatic Agents*
dc.subject.meshTreatment Outcome*
dc.subject.meshHumans*
dc.subject.meshConsensus*
dc.titleSevere T2-high asthma in the biologics era: European experts' opinionen
dc.typereview articleen
dspace.entity.typePublication
relation.isPublisherOfPublicationf180fd5a-01b7-4631-aa13-8dc65d4a7f70
relation.isPublisherOfPublication.latestForDiscoveryf180fd5a-01b7-4631-aa13-8dc65d4a7f70

Files

Collections

IdisBa - Instituto de Investigación Sanitaria Illes Balears (Baleares)